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Introduction
Neoadjuvant chemotherapy is a well-established treatment option for patients with non-metastatic
breast cancer. The patient response is correlated with survival. However, the optimal method for
monitoring neoadjuvant therapy response has not been established. One factor that may affect the
response of neoadjuvant therapy is the interstitial fluid pressure (IFP). Increased IFP prevents an
effective delivery of therapeutic agents and reduces the efficacy of the therapy. Recently,
subharmonic-aided pressure estimation (SHAPE) using contrast-enhanced ultrasound (CEUS) has
been developed and its potential was demonstrated in animals as a non-invasive technique for IFP
measurements. The SHAPE method estimates IFP based on the inverse relationship between the
subharmonic signal magnitude from CEUS and IFP. The purpose of this study was to determine if
4D SHAPE can predict the response of breast cancer to neoadjuvant chemotherapy.

Figure 1: Flowchart of participants in this study

Materials and Methods
A. Subjects
Seventeen women with breast cancer (T1 or greater locally advanced breast cancer) and scheduled
for neoadjuvant chemotherapy (approximately 16 therapy cycles over 3-6 months) participated in
this study and all participants provided written informed consent.
B. Ultrasound examinations
Subjects underwent 4 US exams: immediately prior to therapy, at 10%, 60%, and 100% completion
of neoadjuvant therapy. Ultrasound exams were performed using a modified Logiq 9 scanner with a
4D10L probe (GE Healthcare, Milwaukee, WI, USA). Modified software enabled collection of
radiofrequency (RF) data from a 4D pulse inversion subharmonic imaging mode (transmitting pulses
at 5.8 MHz and receiving at 2.9 MHz). At each exam, 2D US baseline images were first acquired.
Subjects then received a continuous IV infusion of 3 ml of Definity (Lantheus Medical Imaging, N
Billerica, MA, USA) suspended in 50 ml saline via an antecubital vein, with infusion rates of 4 to
10 ml/min (titrated to effect). The acoustic output power used for SHAPE was optimized by running
an automatic power control algorithm during the infusion. This power optimization was performed
only for the exam prior to therapy for each patient and the individual acoustic output power setting
selected was then maintained through the rest of the US exams. After the optimization process, the
infusion was halted for about 5 minutes to allow for clearance of bubbles. Then RF data was
collected with no contrast agent in the 4D SHAPE mode. Infusion was restarted for collection of 3
sets of RF data with contrast agents. The volume rates for 4D data were 0.6 to 3.2 volume/second.
Note, that the infusion interruption happened only for the initial exam in which the output power
optimization was performed.

Figure 2: 3D images of breast cancer acquired at the prior to neoadjuvant therapy (a) and at the 10% completion of therapy (b)
are displayed using 4D View (GE Healthcare, Zipf, Austria). This viewer shows the three orthogonal planes of sagittal (top left),
transverse (top right), and coronal (bottom left) as well as a rendered volume (bottom right). The rendered volume is a
semitransparent representation of all volume pixels within the ROI boxes of the top row.

C. Evaluation of neoadjuvant therapy response
Clinical response was evaluated using the change in 3D tumor volume measurements from the US
baseline images after the completion of neoadjuvant therapy. Subjects with more than 90% tumor
volume reduction were rated as responders, while others were rated as partial/non-responders. This
relatively coarse classification scheme was applied, due to the small sample size in this pilot study.
D. Data analysis
Using baseline images, the 3D tumor size change during therapy was compared to the clinical
response and corresponding SHAPE results. RF data from 4D SHAPE exams were transferred to a
PC for off-line analysis using Matlab (Mathworks, Natick, MA). Two regions of interest (ROI) were
selected in each elevational plane: one within the tumor and the other in the surrounding tissues. Fast
Fourier Transform (FFT) was computed for each A-line within the ROI and all FFTs were averaged
laterally as well as over a volume and frames to obtain a reliable frequency spectrum. The maximum
magnitude from the resultant frequency spectrum was extracted from each pre-infusion and during
infusion data and the ratio was calculated for each ROI. This ratio of subharmonic signal was
calculated to account for possible attenuation change in the ROIs over 4 exams and to include the
subharmonic signal only from the contrast agent. Finally, the difference in the obtained subharmonic
signal ratios from the tumor and the surrounding area was calculated as a relative estimate of IFP.
The results from 3 sets of RF data were averaged and this analysis was repeated for all 4 US exams
of each patient. The obtained subharmonic signal differences between the tumor and surrounding
area in all 4 exams were compared to the final Therapy response. A t-test was used to compare
SHAPE results between responders and partial/non responders with a 5% significance level.

Results
A total of 17 subjects participated in the study (Fig 1). Ultrasound exams were performed in
3D modes and the tumor size change was observed through the therapy. Examples of 3D
images from a subject prior to therapy and at the 10% completion of therapy are presented in
Fig. 2. In this case, tumor size decreased after the therapy (from 4.2cm x 3.5cm x 3.4cm to
3.9cm x 3.5cm x 2.8cm). The tumor size change between the first two exams did not
differentiate responders from partial/non-responders (p > 0.2, data not shown for brevity).
The subharmonic signal changes related to IFP were analyzed over all 4 US exams. The
subharmonic signal increase with contrast agent infusion is shown in Fig. 3 Among SHAPE
results from the 4 exams, only the results after 10% completion of the therapy showed
significance (Fig. 4; p= 0.0011). The initial and final tumor size, tumor reduction rate, and the
results from SHAPE data collected after 10% completion of the therapy are presented in
Table 1. Subjects 9 and 10 did not complete treatment, due to the non-responsiveness, and
underwent surgery after 10% completion of the therapy. Subject 11 was also determined to be
non-responsive and received additional treatment after 10% completion of the therapy. The
results from the SHAPE analysis were positive (subharmonic signal increased more in the
tumor than in the surrounding area) for responders and zero or negative for partial / nonresponders.

Conclusions
Monitoring neoadjuvant therapy at an early stage is challenging and the optimal method has
not been established. In this pilot study, the 4D SHAPE method showed potential to monitor
the clinical response of breast cancer to neoadjuvant chemotherapy as early as at 10%
completion of therapy. As a functional assessment tool, 4D SHAPE may be useful to predict
the neoadjuvant therapy response at an early stage.

Figure 3: Subharmonic images collected before (a) and during the contrast agent infusion (b) for SHAPE (acquired from the
patient after 10% completion of neoadjuvant therapy). The figure shows the three orthogonal planes of sagittal (top left),
transverse (top right), and coronal (bottom left) as well as a rendered volume (bottom right). A tumor is located in the center of
each view (arrows).

Figure 4: 4D SHAPE results from the data collected
after 10% completion of the neoadjuvant therapy for
responders (black bar) vs. partial/non-responders (gray
bar) based on clinical assessment. The bars and error
bars show the mean and standard deviation, respectively.
The symbol * represents significant differences with p <
0.01.

Table 1. Tumor size change and the results from 4D SHAPE data collected after 10% completion of therapy (unit for tumor size:
cm x cm x cm).

Subject
number

Initial
tumor size

Final
tumor size

Tumor volume SHAPE result
reduction
(dB)

1

2.4 x 2.1x 1.6

Undetectable in imaging

100%

2.58

2

3.4 x 2.4 x 2.7

Undetectable in imaging

100%

4.04

3

2.3 x 2.4 x 1.7

Undetectable in imaging

100%

0.88

4

4.2 x 3.5 x 3.4

0.6 x 1.1 x 0.3

99.6%

4.30

5

2.8 x 2.0 x 1.7

0.3 x 0.4 x 0.4

99.5%

4.68

6

3.2 x 2.8 x 2.2

1.0 x 1.0 x1.6

91.9%

2.88

7

1.4 x 1.1 x 1.9

1.0 x 1.0 x 0.9

69.2%

-3.23

8

3.6 x 2.3 x 3.0

2.2 x 1.7x 2.3

65.4%

-1.37

9

3.9 x 4.4 x 4.2

Not available

Not available

0.27

10

1.0 x 1.4 x 1.3

Not available

Not available

0.00

11

4.0 x 3.9 x 2.1

Not available

Not available

-0.07
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